Entry |
|
Name |
Laropiprant (INN/USAN) |
Formula |
C21H19ClFNO4S
|
Exact mass |
435.0707
|
Mol weight |
435.90
|
Structure |

|
Efficacy |
Anti-atherosclerotic, Antidyslipidemia, Prostaglandin D2 receptor antagonist |
Comment |
Treatment of atherosclerosis, dyslipidemia, and conditions when administered with niacin
|
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
|
Brite |
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Prostaglandin
PTGDR
D08940 Laropiprant (INN/USAN)
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 29
1 C8y C 15.6800 -13.2300
2 C8x C 15.6800 -14.6300
3 C8y C 16.8924 -15.3300
4 C8y C 18.1049 -14.6300
5 C8y C 18.1049 -13.2300
6 C8x C 16.8924 -12.5300
7 N4y N 19.4364 -15.0626
8 C8y C 20.2593 -13.9300
9 C8y C 19.4364 -12.7974
10 C1y C 21.5908 -13.4974
11 C1x C 21.5908 -12.0974
12 C1x C 20.2593 -11.6647
13 X F 14.4676 -12.5300
14 S4a S 16.8924 -16.7298
15 C1a C 16.8924 -18.1298
16 O3c O 15.4700 -16.7298
17 O3c O 18.2700 -16.7298
18 C1b C 19.8675 -16.3894
19 C8y C 21.2469 -16.6827
20 C8x C 21.6761 -18.0028
21 C8x C 23.0455 -18.2937
22 C8y C 23.9821 -17.2531
23 C8x C 23.5529 -15.9330
24 C8x C 22.1835 -15.6421
25 X Cl 25.3709 -17.5486
26 C1b C 22.7088 -14.3101
27 C6a C 23.9744 -13.7466
28 O6a O 25.0719 -14.5439
29 O6a O 24.1236 -12.3321
BOND 32
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 1
9 8 9 2
10 5 9 1
11 8 10 1
12 10 11 1
13 11 12 1
14 9 12 1
15 1 13 1
16 3 14 1
17 14 15 1
18 14 16 2
19 14 17 2
20 7 18 1
21 18 19 1
22 19 20 2
23 20 21 1
24 21 22 2
25 22 23 1
26 23 24 2
27 19 24 1
28 22 25 1
29 10 26 1 #Down
30 26 27 1
31 27 28 1
32 27 29 2
|